ARTICLE | Clinical News
PT-141: Phase IIb started
August 8, 2005 7:00 AM UTC
The partners began a 3-month, double-blind, placebo-controlled, dose-ranging, U.S. Phase IIb trial in 560 non-diabetic patients. The trial will evaluate 5-15 mg doses of intranasal PT-141. ...